AKEBIA THERAPEUTICS INC (AKBA) — insider trading
Health Care · NASDAQ
AKEBIA THERAPEUTICS INC (AKBA) has 19 reported SEC Form 4 insider transactions in our data, including 1 open-market purchase and 5 open-market sales among the most recent 19 (latest 2026-06-29).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-06-29 | Ostrowski Erik | Officer (SVP, CFO, CBO & Treasurer) | Open-market sale | 56,019 | $1.11 | $62.2K | Form 4 |
| 2026-06-17 | ADAMS ADRIAN | Director | Grant / award / vesting (derivative) | 53,600 | $0.00 | $0 | Form 4 |
| 2026-06-17 | ADAMS ADRIAN | Director | Grant / award / vesting | 35,700 | $0.00 | $0 | Form 4 |
| 2026-06-17 | ZUMWALT LEANNE M | Director | Grant / award / vesting (derivative) | 53,600 | $0.00 | $0 | Form 4 |
| 2026-06-17 | ZUMWALT LEANNE M | Director | Grant / award / vesting | 35,700 | $0.00 | $0 | Form 4 |
| 2026-06-17 | FRIESON RON | Director | Grant / award / vesting (derivative) | 53,600 | $0.00 | $0 | Form 4 |
| 2026-06-17 | FRIESON RON | Director | Grant / award / vesting | 35,700 | $0.00 | $0 | Form 4 |
| 2026-06-17 | ROGERS MICHAEL W | Director | Grant / award / vesting (derivative) | 53,600 | $0.00 | $0 | Form 4 |
| 2026-06-17 | ROGERS MICHAEL W | Director | Grant / award / vesting | 35,700 | $0.00 | $0 | Form 4 |
| 2026-06-17 | Smith Cynthia | Director | Grant / award / vesting (derivative) | 53,600 | $0.00 | $0 | Form 4 |
| 2026-06-17 | Smith Cynthia | Director | Grant / award / vesting | 35,700 | $0.00 | $0 | Form 4 |
| 2026-06-17 | Wolf Myles | Director | Grant / award / vesting (derivative) | 53,600 | $0.00 | $0 | Form 4 |
| 2026-06-17 | Wolf Myles | Director | Grant / award / vesting | 35,700 | $0.00 | $0 | Form 4 |
| 2026-04-01 | Vickers Philip J. | Director | Grant / award / vesting (derivative) | 214,400 | $0.00 | $0 | Form 4 |
| 2026-03-04 | Butler John P. | Director, Officer (CEO and President) | Open-market purchase | 69,270 | $1.25 | $86.6K | Form 4 |
| 2026-02-02 | Grund Nicholas | Officer (Chief Commercial Officer) | Open-market sale | 31,244 | $1.39 | $43.4K | Form 4 |
| 2026-02-02 | Grund Nicholas | Officer (Chief Commercial Officer) | Open-market sale | 53,585 | $1.39 | $74.5K | Form 4 |
| 2026-02-02 | Malabre Richard C | Officer (SVP, Chief Accounting Officer) | Open-market sale | 13,382 | $1.39 | $18.6K | Form 4 |
| 2026-02-02 | Malabre Richard C | Officer (SVP, Chief Accounting Officer) | Open-market sale | 36,142 | $1.39 | $50.2K | Form 4 |
Ask the chat about AKBA's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: AKEBIA THERAPEUTICS INC (AKBA).
Last updated 2026-06-29 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.